Josep M Llovet

Nov 19, 2024 | bpno.dk | Josep M Llovet

november 2024 Dr. Josep M. Llovet, Liver Cancer Program, Mount Sinai, New York, presents in this MEDtalk the results of the LEAP-012 phase II study of lenvatinib in combination with pembrolizumab plus transarterial chemoembolization for patients with intermediate hepatocellular carcinoma. The results show that the study hit the primary endpoint, progression-free survival for the combination arm.

Oct 7, 2024 | onclive.com | Josep M Llovet

CommentaryVideoOctober 7, 2024Author(s):Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

Oct 26, 2023 | nature.com | Amit Singal |Josep M Llovet

AbstractHepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in the Western world. Cirrhosis remains the predominant risk factor for HCC. However, epidemiological shifts in the incidence of HCC from patients with virus-related liver disease to those with non-viral aetiologies, including alcohol-associated and metabolic dysfunction-associated steatotic liver disease, have important implications for prevention, surveillance and treatment.

Aug 3, 2023 | nature.com | Julia Zhao |Zaigham Khan |Xufen Yu |Ravisankar Rajarethinam |Jian Jin |Augusto Villanueva | +7 more

AbstractHepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. β-Catenin (CTNNB1)-mutated HCC represents 30% of cases of the disease with no precision therapeutics available. Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, we screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples.